Literature DB >> 29971836

Carboplatin and epirubicin combination therapy for advanced malignant epithelial skin tumors: Retrospective study of six patients.

Yoshio Nakamura1, Keiji Tanese1, Ikuko Hirai1, Yutaka Kawakami2, Takeru Funakoshi1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29971836     DOI: 10.1111/1346-8138.14328

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

1.  Three cases of advanced cutaneous squamous cell carcinoma treated with a combination of carboplatin and epirubicin.

Authors:  Mayumi Okamoto; Takanobu Kan; Emi Murakami; Tomofumi Numata; Risa Otsuka; Manami Sueoka; Masaya Moriwaki; Shunsuke Takahagi; Akio Tanaka; Mikio Kawai; Hayato Mizuno; Michihiro Hide
Journal:  Eur J Hosp Pharm       Date:  2019-11-11

Review 2.  Epidermal Growth Factor Receptor's Function in Cutaneous Squamous Cell Carcinoma and Its Role as a Therapeutic Target in the Age of Immunotherapies.

Authors:  Priscila Oliveira de Lima; Shannon Joseph; Benedict Panizza; Fiona Simpson
Journal:  Curr Treat Options Oncol       Date:  2020-02-03

Review 3.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

4.  Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).

Authors:  Maki Ishii; Ikuko Hirai; Keiji Tanese; Takayuki Fusumae; Yoshio Nakamura; Keitaro Fukuda; Hiroshi Uchi; Kenji Kabashima; Atsushi Otsuka; Kenji Yokota; Naoya Yamazaki; Kenjiro Namikawa; Taku Fujimura; Tatsuya Takenouchi; Yuki Yamamoto; Mana Nishiguchi; Yasunori Sato; Masayuki Amagai; Takeru Funakoshi
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.